The analysis of consumption of intestinal anti-inflammatory agents in different countries of the world
Journal Title: Соціальна фармація в охороні здоров’я - Year 2019, Vol 5, Issue 2
Abstract
Aim. To assess drug consumption of the group A07E “Intestinal anti-inflammatory agents” in Ukraine and European countries in 2015-2017. Materials and methods. Data from the “Pharmexplorer” information system of Morion company were used to analyze the assortment and the consumption volumes of intestinal anti-inflammatory agents in Ukraine. The volumes, structure and dynamics of drug consumption of this group in Ukraine was assessed based on the number of the consumed defined daily doses (DDD) of drugs using the ATC/DDD methodology and the number of packs sold. The level of consumption of the drugs studied by the indicator “DDDs/1000 inhabitants/day” in the countries of Europe was determined by the statistical data of these countries. Results. The intestinal anti-inflammatory agents were presented in Ukraine in 2015-2017 in the number of 4 international non-patented names, 22-27 trade names (TN), mainly of foreign production with a high price for a pack. The number of TNs of drugs of this group and volumes of their consumption (by the number of packs sold and the number of the consumed DDDs) increased in Ukraine from 2015 to 2017. The largest number of packs sold was determined for sulfasalazine. The level of consumption of intestinal anti-inflammatory agents by the indicator “DDDs/1000 inhabitants/day” in Ukraine did not correspond to the level of drug consumption of this group in European countries (Norway, Lithuania, Latvia, Estonia) in 2015-2017, and it was the lowest among the countries studied. The largest volumes of drug consumption of this group were determined in Norway. Mesalazine was ranked first by the number of the consumed DDDs in Norway, Lithuania and Estonia in 2015-2017, and sulfasalazine – in Latvia. The leadership of sulfasalazine and mesalazine varied over the years in Ukraine. Conclusions. The volumes of drug consumption of the group A07E “Intestinal anti-inflammatory agents” by the number of packs sold and the number of the consumed DDDs increased in Ukraine from 2015 to 2017. The level of drug consumption of this group by the indicator “DDDs/1000 inhabitants/day” in Ukraine during 2015-2017 did not correspond to the level of consumption of the intestinal anti-inflammatory agents in European countries.
Authors and Affiliations
O. O. Gerasymova, L. V. Iakovlieva, V. O. Taran
Keywords
Related Articles
- EP ID EP663113
- DOI 10.24959/sphhcj.19.151
- Views 156
- Downloads 0
Qualitative composition and quantitative determination of the fatty and organic acids of Rhododendron purdomii R. leaves using gas chromatography – mass spectrometry method
For today the range of herbal medicines constitute about 30-40 % and tend to increase. Herbal remedies usually have a soft complex effect on the human body with the least amount of side effects. In this regard, plants, i...
Determination of pharmacy specialists’ motivation profiles in pharmacy
The identification of the motivation sources, and not the specific need or factor of the pharmacy specialist (PS) motivation, will allow the Pharmacy management depending on the available funds, time, organizational cult...
Assessment of socio-economic availability of spironolactone diuretics (С03DA01) and furosemide (C03CA01) of the domestic pharmaceutical market
The results of market monitoring of diuretics recommended for the treatment of liver cirrhosis complications have been analyzed in the article. From 01/01/2017 till 31/12/2018 a monthly monitoring of the physical and soc...
Marketing aspects of the development of veterinary preparations based on peloids and products of their processing
The use of peloids and their derivatives in veterinary is based on their low toxicity and a wide range of the pharmacological activity due to the multi-component chemical composition аnd significant resources of this raw...
The marketing approach to determining the main indicators of economic efficiency of a hepatotropic drug
Aim. To substantiate the expediency of development of an arginine-based hepatotropic drug using prognostic determination of the main indicators of economic efficiency. Materials and methods. The legislative and regulator...